WASHINGTON — A key House committee is preparing for a hearing on drug pricing, as Republicans show an increasing willingness to examine an issue frustrating their constituents.

Rep. Michael Burgess of Texas, who helms the health subcommittee of the Energy and Commerce Committee, told STAT Thursday his subcommittee will hold a hearing on the drug pricing issues, as well as the related “supply chain.” Neither he nor the full panel chairman, Rep. Greg Walden of Oregon, suggested the hearing had yet been scheduled.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Day of reckoning or artificial song and dance is coming and soon. Lot of hoopla but no concrete results would be the case in our legalized corrupt election system. Legislators need pharmaceutical money to get elected. They will not touch the golden goose.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy